Pharmacogenetics of Trastuzumab Review of literature
Journal of Healthcare · 27.09.2026 · 7 (1) · 175-180
DOI: 10.36959/569/479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Healthcare, online erschienen am 27.09.2026. Verfasst von Ahmed Salih Sahib und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Trastuzumab (Herceptin) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), improving survival rates in patients with HER2-positive breast cancer. Despite its efficacy, treatment responses vary widely among patients, with approximately 23% of early-stage HER2-positive breast cancer patients experiencing no response or recurrence within a decade. This review explores the pharmacogenetic landscape influencing trastuzumab efficacy, focusing on genetic polymorphisms that affect drug metabolism and therapeutic outcomes. Key genetic factors, including variations in the FCGR3A, TP53, HER2, BARD1, FGFR1, MDM2, and ATM genes, are examined for their roles in modulating the immune response and resistance to therapy. Understanding these genetic influences is crucial for optimizing trastuzumab treatment strategies and personalizing therapy to enhance patient outcomes in HER2-positive breast cancer.
Zitieren
APA
Sahib, A. S., & Ali, D. A. A. K. (2026). Pharmacogenetics of Trastuzumab Review of literature. Journal of Healthcare, 7(1), 175-180. https://doi.org/10.36959/569/479
Vancouver
Sahib AS, Ali DAAK. Pharmacogenetics of Trastuzumab Review of literature. Journal of Healthcare. 2026;7(1):175-180. doi:10.36959/569/479
BibTeX
@article{Sahib2026,
author = {Sahib, Ahmed Salih and Ali, Dunia Abd AL Kareem},
title = {Pharmacogenetics of Trastuzumab Review of literature},
journal = {Journal of Healthcare},
year = {2026},
volume = {7},
number = {1},
pages = {175--180},
doi = {10.36959/569/479}
}
EUVIMED